Last reviewed · How we verify
NCT07108712
Diffusion Magnetic Resonance Imaging (dMRI) in the Early Evaluation of Brain White Matter Diseases
trial testing Magnetic Resonance Imaging (MRI) in Diffusion Magnetic Resonance Imaging in 150 participants. Currently enrolling.
1 December 2025
Quick facts
| Lead sponsor | The General Authority for Teaching Hospitals and Institutes |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 150 |
| Start date | 1 May 2025 |
| Primary completion | 1 December 2025 |
| Estimated completion | 1 December 2025 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- Magnetic Resonance Imaging (MRI)
Conditions studied
- Diffusion Magnetic Resonance Imaging — all drugs for Diffusion Magnetic Resonance Imaging →
- Brain White Matter Diseases — all drugs for Brain White Matter Diseases →
Sponsor
The General Authority for Teaching Hospitals and Institutes
Who can join
Adults 18 to 80, any sex, with Diffusion Magnetic Resonance Imaging or Brain White Matter Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To assess the sensitivity and accuracy of diffusion magnetic resonance imaging (MRI), including diffusion-weighted imaging (DWI) metrics, in identifying early-stage changes in brain white matter related to various white matter diseases.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07108712
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Magnetic Resonance Imaging (MRI)
Trials testing the same drug.
- NCT07226453 — Target Validation and Efficacy of Metformin in Patients With Posterior Fossa Group A (PFA) Ependymoma · Phase 2 · not yet recruiting
- NCT07346170 — Short Interval Postoperative Stereotactic Body Radiation Therapy (SBRT) After Surgical Intervention for Spine Metastases · NA · not yet recruiting
- NCT07110246 — Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas · Phase 2 · recruiting
- NCT07185958 — Dual Energy CT - a Tool for Delineation of Tumor and Organs at Risk in Radiotherapy · not yet recruiting
- NCT06492057 — Electromyostimulation (EMS) of Astronauts in Spaceflight (Easymotion-2) · NA · enrolling by invitation
Other recruiting trials for Diffusion Magnetic Resonance Imaging
Currently open trials in the same condition.
- NCT05843084 — The STEREO-DBS Study: 7-Tesla MRI Brain Network Analysis for Deep Brain Stimulation · recruiting
Other The General Authority for Teaching Hospitals and Institutes trials
Trials by the same sponsor.
- NCT07295704 — Micropulse Laser in Treatment of Initial and Refractory Cases of Center-Involved Diabetic Macular Edema · recruiting
- NCT07295691 — Autologous Serum Eye Drops in Dry Eye Syndrome · NA · recruiting
- NCT07125794 — Original Denis Brawn Brace Versus Its Modification for Management of Relapsed Idiopathic Clubfoot Following Ponseti Cast · recruiting
- NCT07108725 — Non-invasive Diffusion-weighted Imaging With MRCP in the Diagnosis of Neoplastic Biliary Obstruction · recruiting
- NCT06928844 — Role of Low Dose Injectable Progesterone in Triggering Ovulation · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07108712 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The General Authority for Teaching Hospitals and Institutes
- Last refreshed: 7 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07108712.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing